New Delhi: India on Wednesday recorded a total of 36,604 fresh COVID-19 infections, taking the total tally to 94,99,414. With 501 new deaths, the toll mounted to 1,38,122. Further, the number of people recuperating from the disease rose to 89,32,647 today as 43,062 new discharges were reported in the last 24 hours.
Here are top points from this story:
1) The active Covid-19 caseload remained below 5 lakh for the 22nd consecutive day. There are 4,28,644 active coronavirus infections in the country which comprises 4.51 per cent of the total caseload, the data stated.
2) India’s Covid-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5. It went past 50 lakh on September 16, 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, and surpassed 90 lakh on November 20.
3) According to the ICMR, 14,24,45,949 samples have been tested up to December 1 with 10,96,651 samples being tested on Tuesday.
4) Following an adverse event during the clinical human trials of Oxford-AstraZeneca’s ‘Covishield’ conducted by Pune-based Serum Institute of India (SII), the government has assured that the causality assessment of the mishap did not necessitate a stoppage of the vaccine trial, nor will it impact its timely rollout.
5) The Phase-III clinical trial of Covid-19 vaccine (Covaxin) being developed by Bharat Biotech would begin at the privately-run Vydehi multi-specialty hospital from Wednesday. “The ICMR (Indian Council of Medical Research) has permitted our hospital to conduct the third phase trial for Covaxin developed by the Hyderabad-based Bharat Biotech,” Vydehi Institute of Medical Sciences and Research Centre official K Ravi Babu had told IANS on Tuesday.